Sweden In-Vitro Diagnostics Market Trends

Name: Sweden In-Vitro Diagnostics Market Trends | Analysis 2030
Creator: Next Move Strategy Consulting
Published: 2025-10-23T20:00:00-04:00
License: https://www.nextmsc.com/privacy-policy

About Report

Download Now

Sweden In-Vitro Diagnostic Market by Product & Service (Reagents & Consumables, Instruments & Devices, and Software & Services), by Technique (Clinical Chemistry, Immunoassays, Molecular Diagnostics, and Others), by Testing Site / Channel (Central & Reference Laboratories, Hospital & Physician Labs, Point-of-Care & Retail, and Others), by Application / Disease Area (Infectious Diseases, Oncology, and others)– Opportunity Analysis and Industry Forecast, 2024–2030.

Download PDF

Speak to Our Analyst

Sweden In-Vitro Diagnostics Market Overview

The Sweden In-Vitro Diagnostics Market size was valued at USD 629.43 million in 2023, and is predicted to reach USD 910.96 million by 2030, at a CAGR of 5.0% from 2024 to 2030. In-vitro diagnostics (IVD) refers to a wide range of medical tests conducted on samples of bodily fluids, tissues, or cells outside of the body to diagnose diseases, monitor therapy, and assess overall health conditions. These tests are performed in laboratory settings using various techniques and technologies, including immunoassays, molecular diagnostics, clinical chemistry, hematology, and microbiology.

These tests enable early detection of diseases, allowing for timely intervention and treatment initiation. By providing rapid and accurate results, IVD tests facilitate personalized medicine, guiding tailored treatment approaches based on individual patient characteristics.

Also, in-vitro experiments provide valuable insights into biological systems, enabling scientists and researchers to make significant contributions to fields such as medicine, biotechnology, and pharmacology. They serve as essential tools for understanding fundamental biological processes and developing innovative solutions to address health challenges.

Strong Publicly Funded Healthcare System Supports IVD Adoption

Sweden’s universal, tax-funded healthcare system ensures high accessibility to medical services, creating a stable foundation for diagnostic testing demand. With sustained government investment in preventive care, early detection, and advanced treatments, IVD products gain continuous relevance. The emphasis on evidence-based medicine further drives adoption of accurate and reliable diagnostic tools, reinforcing the market’s long-term expansion.

Growing Emphasis on Personalized Medicine and Molecular Testing

The rising use of genomics, molecular diagnostics, and biomarker-driven therapies is fueling demand for advanced IVD solutions. Sweden’s strong research ecosystem, combined with collaborations between hospitals, academic institutions, and biotech companies, accelerates the adoption of precision diagnostics. These developments support tailored treatment strategies, boosting the role of IVD across oncology, infectious diseases, and chronic illness management.

Complex Regulatory Framework and Cost Pressures Limit Market Growth

The implementation of the EU In Vitro Diagnostic Regulation (IVDR) has increased compliance costs for manufacturers operating in Sweden. Extensive documentation, clinical performance studies, and post-market surveillance requirements delay product approvals and strain smaller companies. Additionally, reimbursement constraints and strict cost-effectiveness evaluations by Swedish health authorities create barriers for new entrants, slowing the availability of innovative diagnostic solutions in the market.

Digital Health Integration and Remote Testing Open New Avenues

The increasing integration of digital health platforms, telemedicine, and remote monitoring is creating opportunities for next-generation IVD solutions. Home-based testing kits, connected diagnostic devices, and AI-enabled decision-support tools align with Sweden’s digital-first healthcare strategies. These innovations enhance patient engagement, improve efficiency in chronic disease management, and expand diagnostic access across urban and rural populations, offering significant growth potential for the IVD industry.

Competitive Landscape

The promising players operating in the Sweden in-vitro diagnostics industry include F. Hoffmann-La Roche AG (Roche Diagnostics), Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Beckman Coulter AB, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., DiaSorin S.p.A., Becton, Dickinson and Company, Hologic, Inc., Fujirebio Holdings, Inc., Bio-Rad Laboratories, Inc., Immunovia AB, Revvity, Inc.., and others.

Sweden In-Vitro Diagnostic Market Key Segments

By Product & Service

Reagents & Consumables
- Clinical Chemistry Reagents
- Immunoassay Reagents (ELISA/CLIA)
- Molecular Master Mixes
- Hematology Controls
Instruments & Devices
- Chemistry Analyzers
- Immunoassay Systems
- Molecular Thermocyclers/Sequencers
- Hematology Analyzers
- POC Devices
Software & Services
- LIS, Data Analytics
- CRO/Testing Services

By Technique

Clinical Chemistry
- Metabolites
- Electrolytes
- Enzymes
Immunoassays
- ELISA / CLIA / CMIA
- Lateral-flow Rapid Tests
- Immunofluorescence
Molecular Diagnostics
- PCR
- Isothermal NAAT
- NGS
- In-situ Hybridization
Hematology & Coagulation
- CBC Analyzers
- Coagulation Panels
Microbiology
- Culture & Sensitivity
- MALDI-TOF
- Molecular ID
Urinalysis & Body Fluids
Other Techniques

By Testing Site / Channel

Central & Reference Laboratories
Hospital & Physician Labs
Point-of-Care & Retail
Home & Self-Testing

By Application / Disease Area

Infectious Diseases
Oncology
Cardiovascular Health
Endocrinology & Diabetes
Nephrology
Genetic & Prenatal Testing
Autoimmune Disorders
Drug Monitoring & Toxicology
Blood Screening & Typing
Other Indications

Key Players

F. Hoffmann-La Roche AG (Roche Diagnostics)
Abbott Laboratories
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Beckman Coulter AB
bioMérieux SA
Sysmex Corporation
QIAGEN N.V.
DiaSorin S.p.A.
Becton, Dickinson and Company
Hologic, Inc.
Fujirebio Holdings, Inc.
Bio-Rad Laboratories, Inc.
Immunovia AB
Revvity, Inc.

Report Scope and Segmentation

Parameters	Details
Market Size Value in 2023	USD 629.43 million
Revenue Forecast in 2030	USD 910.96 million
Value Growth Rate	CAGR of 5.0% from 2024 to 2030
Analysis Period	2023–2030
Base Year Considered	2023
Forecast Period	2024–2030
Market Size Estimation	Million (USD)
Growth Factors	Strong Publicly Funded Healthcare System Supports Ivd Adoption Growing Emphasis On Personalized Medicine And Molecular Testing
Companies Profiled	15
Customization Scope	Free customization (equivalent up to 80 working hours of analysts) after purchase. Addition or alteration to country, regional, and segment scope.
Pricing and Purchase Options	Avail customized purchase options to meet your exact research needs.

About the Author

Sikha Haritwal is an assistant manager with strong expertise in market research, data analysis, and cross-functional coordination. She plays a key role in leading complex research initiatives, strengthening analytical rigor, and enabling data-driven decision-making across teams. Known for her leadership mindset and structured problem-solving approach, she supports process improvement, enhances operational efficiency, and contributes to building scalable frameworks that drive long-term strategic outcomes and organizational effectiveness.

About the Reviewer

Supradip Baul is an accomplished business consultant and strategist with over a decade of rich experience in market intelligence, strategy, technology, and business transformation. His work has included rigorous qualitative and quantitative analysis across multiple industries, helping clients shape investment decisions and long-term roadmaps. Earlier in his career, he was associated with Gartner, where he contributed to industry-leading reports and market share analyses. He has worked with leading global companies and holds an MBA with a dual specialization in Marketing and Finance.

1. 1.1. REPORT DESCRIPTION
2. 1.2. WHO SHOULD READ THIS REPORT
3. 1.3. KEY MARKET SEGMENTS
4. 1.4. RESEARCH METHODOLOGY
5. 1. 1.4.1 MARKET SIZE ESTIMATION METHODOLOGY
  2. 1. 1.4.1.1. TOP-DOWN AND BOTTOM-UP APPROACH
    2. 1.4.1.2. DEMAND AND SUPPLY-SIDE ANALYSIS
    3. 1.4.1.3. MACRO-INDICATOR APPROACH
  3. 1.4.2 DATA COLLECTION APPROACH
  4. 1. 1.4.2.1. PRIMARY DATA COLLECTION
    2. 1.4.2.2. SECONDARY DATA COLLECTION
  5. 1.4.3 SECONDARY DATA SOURCES
  6. 1.4.4 FORECASTING

1. 2.1. DEFINITION
2. 2.2. SCOPE

1. 3.1. MARKET SNAPSHOT, 2024 - 2030, MILLION USD

1. 4.1. MARKET DYNAMICS
2. 1. 4.1.1 DRIVERS
  2. 1. 4.1.1.1. STRONG PUBLICLY FUNDED HEALTHCARE SYSTEM SUPPORTS IVD ADOPTION
    2. 4.1.1.2. GROWING EMPHASIS ON PERSONALIZED MEDICINE AND MOLECULAR TESTING
  3. 4.1.2 RESTRAINTS
  4. 1. 4.1.2.1. COMPLEX REGULATORY FRAMEWORK AND COST PRESSURES LIMIT MARKET GROWTH
  5. 4.1.3 OPPORTUNITIES
  6. 1. 4.1.3.1. DIGITAL HEALTH INTEGRATION AND REMOTE TESTING OPEN NEW AVENUES

1. 5.1. MARKET SHARE ANALYSIS OF TOP 10 SWEDEN IN-VITRO DIAGNOSTICS PROVIDERS, 2024

1. 6.1 OVERVIEW
2. 6.2 REAGENTS AND CONSUMABLES MARKET
3. 1. 6.2.1 CLINICAL CHEMISTRY REAGENTS
  2. 6.2.2 IMMUNOASSAY REAGENTS (ELISA/CLIA)
  3. 6.2.3 MOLECULAR MASTER MIXES
  4. 6.2.4 HEMATOLOGY CONTROLS
4. 6.3 INSTRUMENTS AND DEVICES MARKET
5. 1. 6.3.1 CHEMISTRY ANALYZERS
  2. 6.3.2 IMMUNOASSAY SYSTEMS
  3. 6.3.3 MOLECULAR THERMOCYCLERS/SEQUENCERS
  4. 6.3.4 HEMATOLOGY ANALYZERS
  5. 6.3.5 POC DEVICES
6. 6.4 SOFTWARE AND SERVICES MARKET
7. 1. 6.4.1 LIS, DATA ANALYTICS
  2. 6.4.2 CRO/TESTING SERVICES

1. 7.1 OVERVIEW
2. 7.2 CLINICAL CHEMISTRY MARKET
3. 1. 7.2.1 METABOLITES
  2. 7.2.2 ELECTROLYTES
  3. 7.2.3 ENZYMES
4. 7.3 IMMUNOASSAYS MARKET
5. 1. 7.3.1 ELISA / CLIA / CMIA
  2. 7.3.2 LATERAL-FLOW RAPID TESTS
  3. 7.3.3 IMMUNOFLUORESCENCE
6. 7.4 MOLECULAR DIAGNOSTICS MARKET
7. 1. 7.4.1 PCR
  2. 7.4.2 ISOTHERMAL NAAT
  3. 7.4.3 NGS
  4. 7.4.4 IN-SITU HYBRIDIZATION
8. 7.5 HEMATOLOGY AND COAGULATION MARKET
9. 1. 7.5.1 CBC ANALYZERS
  2. 7.5.2 COAGULATION PANELS

1. 7.6 MICROBIOLOGY MARKET
2. 1. 7.6.1 CULTURE AND SENSITIVITY
  2. 7.6.2 MALDI-TOF
  3. 7.6.3 MOLECULAR ID
3. 7.7 URINALYSIS AND BODY FLUIDS MARKET
4. 7.8 OTHER TECHNIQUES MARKET

1. 8.1 OVERVIEW
2. 8.2 CENTRAL AND REFERENCE LABORATORIES MARKET
3. 8.3 HOSPITAL AND PHYSICIAN LABS MARKET
4. 8.4 POINT-OF-CARE AND RETAIL MARKET
5. 8.5 HOME AND SELF-TESTING MARKET

1. 9.1 OVERVIEW
2. 9.2 INFECTIOUS DISEASES MARKET
3. 9.3 ONCOLOGY MARKET
4. 9.4 CARDIOVASCULAR HEALTH MARKET
5. 9.5 ENDOCRINOLOGY AND DIABETES MARKET
6. 9.6 NEPHROLOGY MARKET
7. 9.7 GENETIC AND PRENATAL TESTING MARKET
8. 9.8 AUTOIMMUNE DISORDERS MARKET
9. 9.9 DRUG MONITORING AND TOXICOLOGY MARKET
10. 9.10 BLOOD SCREENING AND TYPING MARKET
11. 9.11 OTHER INDICATIONS MARKET

1. 10.1 F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS)
2. 1. 10.1.1 COMPANY OVERVIEW
  2. 10.1.2 COMPANY SNAPSHOT
  3. 10.1.3 OPERATING BUSINESS SEGMENTS
  4. 10.1.4 PRODUCT PORTFOLIO
  5. 10.1.5 BUSINESS PERFORMANCE
  6. 10.1.6 BUSINESS SEGMENTS
  7. 10.1.7 GEOGRAPHIC SEGMENTS
  8. 10.1.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.1.9 PRIMARY MARKET COMPETITORS
3. 10.2 ABBOTT LABORATORIES
4. 1. 10.2.1 COMPANY OVERVIEW
  2. 10.2.2 COMPANY SNAPSHOT
  3. 10.2.3 OPERATING BUSINESS SEGMENTS
  4. 10.2.4 PRODUCT PORTFOLIO
  5. 10.2.5 BUSINESS PERFORMANCE
  6. 10.2.6 BUSINESS SEGMENTS
  7. 10.2.7 GEOGRAPHIC SEGMENTS
  8. 10.2.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.2.9 PRIMARY MARKET COMPETITORS
5. 10.3 SIEMENS HEALTHINEERS AG
6. 1. 10.3.1 COMPANY OVERVIEW
  2. 10.3.2 COMPANY SNAPSHOT
  3. 10.3.3 OPERATING BUSINESS SEGMENTS
  4. 10.3.4 PRODUCT PORTFOLIO
  5. 10.3.5 BUSINESS PERFORMANCE
  6. 10.3.6 BUSINESS SEGMENTS
  7. 10.3.7 GEOGRAPHIC SEGMENTS
  8. 10.3.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.3.9 PRIMARY MARKET COMPETITORS
7. 10.4 THERMO FISHER SCIENTIFIC INC.
8. 1. 10.4.1 COMPANY OVERVIEW
  2. 10.4.2 COMPANY SNAPSHOT
  3. 10.4.3 OPERATING BUSINESS SEGMENTS
  4. 10.4.4 PRODUCT PORTFOLIO
  5. 10.4.5 BUSINESS PERFORMANCE
  6. 10.4.6 BUSINESS SEGMENTS
  7. 10.4.7 GEOGRAPHIC SEGMENTS
  8. 10.4.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.4.9 PRIMARY MARKET COMPETITORS
9. 10.5 BECKMAN COULTER AB
10. 1. 10.5.1 COMPANY OVERVIEW
  2. 10.5.2 COMPANY SNAPSHOT
  3. 10.5.3 OPERATING BUSINESS SEGMENTS
  4. 10.5.4 PRODUCT PORTFOLIO
  5. 10.5.5 BUSINESS PERFORMANCE
  6. 10.5.6 BUSINESS SEGMENTS
  7. 10.5.7 GEOGRAPHIC SEGMENTS
  8. 10.5.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.5.9 PRIMARY MARKET COMPETITORS
11. 10.6 BIOMéRIEUX SA
12. 1. 10.6.1 COMPANY OVERVIEW
  2. 10.6.2 COMPANY SNAPSHOT
  3. 10.6.3 OPERATING BUSINESS SEGMENTS
  4. 10.6.4 PRODUCT PORTFOLIO
  5. 10.6.5 BUSINESS PERFORMANCE
  6. 10.6.6 BUSINESS SEGMENTS
  7. 10.6.7 GEOGRAPHIC SEGMENTS
  8. 10.6.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.6.9 PRIMARY MARKET COMPETITORS

1. 10.7 SYSMEX CORPORATION
2. 1. 10.7.1 COMPANY OVERVIEW
  2. 10.7.2 COMPANY SNAPSHOT
  3. 10.7.3 OPERATING BUSINESS SEGMENTS
  4. 10.7.4 PRODUCT PORTFOLIO
  5. 10.7.5 BUSINESS PERFORMANCE
  6. 10.7.6 BUSINESS SEGMENTS
  7. 10.7.7 GEOGRAPHIC SEGMENTS
  8. 10.7.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.7.9 PRIMARY MARKET COMPETITORS
3. 10.8 QIAGEN N.V.
4. 1. 10.8.1 COMPANY OVERVIEW
  2. 10.8.2 COMPANY SNAPSHOT
  3. 10.8.3 OPERATING BUSINESS SEGMENTS
  4. 10.8.4 PRODUCT PORTFOLIO
  5. 10.8.5 BUSINESS PERFORMANCE
  6. 10.8.6 BUSINESS SEGMENTS
  7. 10.8.7 GEOGRAPHIC SEGMENTS
  8. 10.8.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.8.9 PRIMARY MARKET COMPETITORS
5. 10.9 DIASORIN S.P.A.
6. 1. 10.9.1 COMPANY OVERVIEW
  2. 10.9.2 COMPANY SNAPSHOT
  3. 10.9.3 OPERATING BUSINESS SEGMENTS
  4. 10.9.4 PRODUCT PORTFOLIO
  5. 10.9.5 BUSINESS PERFORMANCE
  6. 10.9.6 BUSINESS SEGMENTS
  7. 10.9.7 GEOGRAPHIC SEGMENTS
  8. 10.9.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.9.9 PRIMARY MARKET COMPETITORS
7. 10.10 BECTON, DICKINSON AND COMPANY
8. 1. 10.10.1 COMPANY OVERVIEW
  2. 10.10.2 COMPANY SNAPSHOT
  3. 10.10.3 OPERATING BUSINESS SEGMENTS
  4. 10.10.4 PRODUCT PORTFOLIO
  5. 10.10.5 BUSINESS PERFORMANCE
  6. 10.10.6 BUSINESS SEGMENTS
  7. 10.10.7 GEOGRAPHIC SEGMENTS
  8. 10.10.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.10.9 PRIMARY MARKET COMPETITORS
9. 10.11 HOLOGIC, INC.
10. 1. 10.11.1 COMPANY OVERVIEW
  2. 10.11.2 COMPANY SNAPSHOT
  3. 10.11.3 OPERATING BUSINESS SEGMENTS
  4. 10.11.4 PRODUCT PORTFOLIO
  5. 10.11.5 BUSINESS PERFORMANCE
  6. 10.11.6 BUSINESS SEGMENTS
  7. 10.11.7 GEOGRAPHIC SEGMENTS
  8. 10.11.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.11.9 PRIMARY MARKET COMPETITORS
11. 10.12 FUJIREBIO HOLDINGS, INC.
12. 1. 10.12.1 COMPANY OVERVIEW
  2. 10.12.2 COMPANY SNAPSHOT
  3. 10.12.3 OPERATING BUSINESS SEGMENTS
  4. 10.12.4 PRODUCT PORTFOLIO
  5. 10.12.5 BUSINESS PERFORMANCE
  6. 10.12.6 BUSINESS SEGMENTS
  7. 10.12.7 GEOGRAPHIC SEGMENTS
  8. 10.12.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.12.9 PRIMARY MARKET COMPETITORS
13. 10.13 BIO-RAD LABORATORIES, INC.
14. 1. 10.13.1 COMPANY OVERVIEW
  2. 10.13.2 COMPANY SNAPSHOT
  3. 10.13.3 OPERATING BUSINESS SEGMENTS
  4. 10.13.4 PRODUCT PORTFOLIO
  5. 10.13.5 BUSINESS PERFORMANCE
  6. 10.13.6 BUSINESS SEGMENTS
  7. 10.13.7 GEOGRAPHIC SEGMENTS
  8. 10.13.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.13.9 PRIMARY MARKET COMPETITORS
15. 10.14 IMMUNOVIA AB
16. 1. 10.14.1 COMPANY OVERVIEW
  2. 10.14.2 COMPANY SNAPSHOT
  3. 10.14.3 OPERATING BUSINESS SEGMENTS
  4. 10.14.4 PRODUCT PORTFOLIO
  5. 10.14.5 BUSINESS PERFORMANCE
  6. 10.14.6 BUSINESS SEGMENTS
  7. 10.14.7 GEOGRAPHIC SEGMENTS
  8. 10.14.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.14.9 PRIMARY MARKET COMPETITORS
17. 10.15 REVVITY, INC.
18. 1. 10.15.1 COMPANY OVERVIEW
  2. 10.15.2 COMPANY SNAPSHOT
  3. 10.15.3 OPERATING BUSINESS SEGMENTS
  4. 10.15.4 PRODUCT PORTFOLIO
  5. 10.15.5 BUSINESS PERFORMANCE
  6. 10.15.6 BUSINESS SEGMENTS
  7. 10.15.7 GEOGRAPHIC SEGMENTS
  8. 10.15.8 KEY STRATEGIC MOVES AND DEVELOPMENT
  9. 10.15.9 PRIMARY MARKET COMPETITORS

TABLE 1. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
TABLE 2. REAGENTS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 3. INSTRUMENTS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 4. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 5. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (MILLION USD)
TABLE 6. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 7. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 8. RAPID TESTS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 9. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 10. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 11. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 12. WESTERN BLOT, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 13. HEMATOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 14. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 15. PCR, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 16. INAAT, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 17. HYBRIDIZATION, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 18. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 19. MICROARRAY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 20. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 21. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 22. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 23. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 24. LIVER PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 25. RENAL PROFILE, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 26. LIPID PROFILE, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 27. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 28. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 29. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 30. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 31. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (MILLION USD)
TABLE 32. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 33. CANCER, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 34. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 35. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 36. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 37. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 38. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 39. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (MILLION USD)
TABLE 40. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 41. HOSPITALS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 42. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 43. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 44. OTHER END-USERS, MARKET VALUE, 2024-2030, (MILLION USD)
TABLE 45. ROCHE HOLDING AG: COMPANY SNAPSHOT
TABLE 46. ROCHE HOLDING AG: OPERATING BUSINESS SEGMENTS
TABLE 47. ROCHE HOLDING AG: PRODUCT PORTFOLIO
TABLE 48. ROCHE HOLDING AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 49. ROCHE HOLDING AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 50. ROCHE HOLDING AG: KEY STRATERGY
TABLE 51. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 52. ABBOTT LABORATORIES: OPERATING BUSINESS SEGMENTS
TABLE 53. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 54. ABBOTT LABORATORIES: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 55. ABBOTT LABORATORIES: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 56. ABBOTT LABORATORIES: KEY STRATERGY
TABLE 57. THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT
TABLE 58. THERMO FISHER SCIENTIFIC INC: OPERATING BUSINESS SEGMENTS
TABLE 59. THERMO FISHER SCIENTIFIC INC: PRODUCT PORTFOLIO
TABLE 60. THERMO FISHER SCIENTIFIC INC: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 61. THERMO FISHER SCIENTIFIC INC: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 62. THERMO FISHER SCIENTIFIC INC: KEY STRATERGY
TABLE 63. DANAHER CORPORATION: COMPANY SNAPSHOT
TABLE 64. DANAHER CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 65. DANAHER CORPORATION: PRODUCT PORTFOLIO
TABLE 66. DANAHER CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 67. DANAHER CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 68. DANAHER CORPORATION: KEY STRATERGY
TABLE 69. BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
TABLE 70. BECTON, DICKINSON AND COMPANY: OPERATING BUSINESS SEGMENTS
TABLE 71. BECTON, DICKINSON AND COMPANY: PRODUCT PORTFOLIO
TABLE 72. BECTON, DICKINSON AND COMPANY: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 73. BECTON, DICKINSON AND COMPANY: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 74. BECTON, DICKINSON AND COMPANY: KEY STRATERGY
TABLE 75. SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
TABLE 76. SIEMENS HEALTHINEERS AG: OPERATING BUSINESS SEGMENTS
TABLE 77. SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO
TABLE 78. SIEMENS HEALTHINEERS AG: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 79. SIEMENS HEALTHINEERS AG: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 80. SIEMENS HEALTHINEERS AG: KEY STRATERGY
TABLE 81. BIOMéRIEUX SA: COMPANY SNAPSHOT
TABLE 82. BIOMéRIEUX SA: OPERATING BUSINESS SEGMENTS
TABLE 83. BIOMéRIEUX SA: PRODUCT PORTFOLIO
TABLE 84. BIOMéRIEUX SA: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 85. BIOMéRIEUX SA: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 86. BIOMéRIEUX SA: KEY STRATERGY
TABLE 87. SYSMEX CORPORATION: COMPANY SNAPSHOT
TABLE 88. SYSMEX CORPORATION: OPERATING BUSINESS SEGMENTS
TABLE 89. SYSMEX CORPORATION: PRODUCT PORTFOLIO
TABLE 90. SYSMEX CORPORATION: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 91. SYSMEX CORPORATION: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 92. SYSMEX CORPORATION: KEY STRATERGY
TABLE 93. QIAGEN N.V.: COMPANY SNAPSHOT
TABLE 94. QIAGEN N.V.: OPERATING BUSINESS SEGMENTS
TABLE 95. QIAGEN N.V.: PRODUCT PORTFOLIO
TABLE 96. QIAGEN N.V.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 97. QIAGEN N.V.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 98. QIAGEN N.V.: KEY STRATERGY
TABLE 99. BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
TABLE 100. BIO-RAD LABORATORIES, INC.: OPERATING BUSINESS SEGMENTS
TABLE 101. BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
TABLE 102. BIO-RAD LABORATORIES, INC.: SALES BY BUSINESS SEGMENTS (2022-2024)
TABLE 103. BIO-RAD LABORATORIES, INC.: SALES BY GEOGRAPHIC SEGMENTS (2022-2024)
TABLE 104. BIO-RAD LABORATORIES, INC.: KEY STRATERGY

FIGURE 1. BARGAINING POWER OF SUPPLIERS
FIGURE 2. BARGAINING POWER OF BUYERS
FIGURE 3. DEGREE OF COMPETITION
FIGURE 4. THREAT OF SUBSTITUTE
FIGURE 5. THREAT OF NEW ENTRANTS
FIGURE 6. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY PRODUCT TYPE, 2024-2030, (MILLION USD)
FIGURE 7. REAGENTS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 8. INSTRUMENTS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 9. SOFTWARE AND SERVICES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 10. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY TECHNIQUE, 2024-2030, (MILLION USD)
FIGURE 11. IMMUNODIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 12. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 13. RAPID TESTS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 14. CHEMILUMINESCENCE IMMUNOASSAY (CLIA), MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 15. ENZYME-LINKED IMMUNOSORBENT SPOT (ELISPOT), MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 16. RADIOIMMUNOASSAY (RIA), MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 17. WESTERN BLOT, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 18. HEMATOLOGY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 19. MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 20. PCR, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 21. INAAT, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 22. HYBRIDIZATION, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 23. DNA DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 24. MICROARRAY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 25. OTHER MOLECULAR DIAGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 26. TISSUE DISGNOSTICS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 27. CLINICAL CHEMISTRY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 28. BASIC METABOLIC PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 29. LIVER PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 30. RENAL PROFILE, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 31. LIPID PROFILE, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 32. THYROID FUNCTION PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 33. ELECTROLYTE PANEL, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 34. SPECIALITY CHEMICALS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 35. OTHER IVD TECHNIQUES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 36. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY APPLICATION, 2024-2030, (MILLION USD)
FIGURE 37. INFECTIOUS DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 38. CANCER, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 39. CARDIAC DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 40. IMMUNE SYSTEM DISORDERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 41. NEPHROLOGICAL DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 42. GASTROINTESTINAL DISEASES, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 43. OTHER INDICATIONS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 44. SWEDEN IN VITRO DIAGONOSTIC MARKET VALUE, BY END-USER, 2024-2030, (MILLION USD)
FIGURE 45. STAND ALONE LABORATORY, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 46. HOSPITALS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 47. ACADEMICS AND MEDICAL SCHOOLS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 48. POINT OF CARE TESTING, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 49. OTHER END-USERS, MARKET VALUE, 2024-2030, (MILLION USD)
FIGURE 50. ROCHE HOLDING AG: NET SALES, (2022-2024)
FIGURE 51. ROCHE HOLDING AG: PRIMARY MARKET COMPETITORS
FIGURE 52. ABBOTT LABORATORIES: NET SALES, (2022-2024)
FIGURE 53. ABBOTT LABORATORIES: PRIMARY MARKET COMPETITORS
FIGURE 54. THERMO FISHER SCIENTIFIC INC: NET SALES, (2022-2024)
FIGURE 55. THERMO FISHER SCIENTIFIC INC: PRIMARY MARKET COMPETITORS
FIGURE 56. DANAHER CORPORATION: NET SALES, (2022-2024)
FIGURE 57. DANAHER CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 58. BECTON, DICKINSON AND COMPANY: NET SALES, (2022-2024)
FIGURE 59. BECTON, DICKINSON AND COMPANY: PRIMARY MARKET COMPETITORS
FIGURE 60. SIEMENS HEALTHINEERS AG: NET SALES, (2022-2024)
FIGURE 61. SIEMENS HEALTHINEERS AG: PRIMARY MARKET COMPETITORS
FIGURE 62. BIOMéRIEUX SA: NET SALES, (2022-2024)
FIGURE 63. BIOMéRIEUX SA: PRIMARY MARKET COMPETITORS
FIGURE 64. SYSMEX CORPORATION: NET SALES, (2022-2024)
FIGURE 65. SYSMEX CORPORATION: PRIMARY MARKET COMPETITORS
FIGURE 66. QIAGEN N.V.: NET SALES, (2022-2024)
FIGURE 67. QIAGEN N.V.: PRIMARY MARKET COMPETITORS
FIGURE 68. BIO-RAD LABORATORIES, INC.: NET SALES, (2022-2024)
FIGURE 69. BIO-RAD LABORATORIES, INC.: PRIMARY MARKET COMPETITORS

At Next Move Strategy Consulting, we understand that insightful market research is the cornerstone of successful business decisions. That's why we employ a robust and multifaceted approach, combining various methodologies to deliver the most accurate and actionable data for our clients.

Research Landscape

We navigate the world of research with two primary approaches:

Qualitative Approach

Our qualitative research methodologies involve immersive techniques such as in-depth interviews, focus groups, and observational studies. By engaging directly with individuals and stakeholders, we uncover valuable insights that quantitative data alone may overlook.

Quantitative Research

In tandem with qualitative methodologies, NMSC leverages the power of Quantitative Research to provide a robust foundation of numerical insights. Through systematic data collection and analysis, we quantify patterns, preferences, and market trends, offering a comprehensive view of the business landscape.

Our quantitative research approach employs diverse tools, including surveys, experiments, and statistical modelling. These methodologies enable us to gather data from a large and representative sample, ensuring the statistical significance of our findings. By employing structured questionnaires and standardized data collection methods, we guarantee the reliability and validity of the information we present to our clients.

Quantitative research is particularly effective in measuring the prevalence of trends, assessing market size, and gauging the impact of various factors on consumer behavior. The numerical precision attained through this approach equips our clients with actionable insights, facilitating data-driven decision-making and strategy formulation.

Our Specialized Toolbox for Industry-Specific Market Research

We deploy a specialized arsenal of techniques tailored to meet your unique requirements. Here's a glimpse into our comprehensive toolbox:

Information Procurement

The stage entails acquiring market data or relevant information through various sources and methodologies.

Market Research Approach

We utilize both top-down and bottom-up approaches in market research analysis to achieve a comprehensive understanding of the market dynamics, leveraging the broad perspective of industry trends and macroeconomic factors alongside detailed insights from specific segments and individual companies.

Porters Five Forces Analysis

We conduct Porter's Five Forces analysis to evaluate the competitive landscape of an industry, providing us with insights into factors that affect profitability and strategic positioning.

SWOT Analysis

Forecasting

We utilize a forecasting model to predict future consumption by considering parameters like population, economics, regulations, market competition, drivers, constraints, technology, and pricing. We also employ statistical techniques such as multilinear regression, exponential smoothing, moving average, ARIMA, and Monte Carlo simulations for accurate predictions. In econometric forecasting, we analyzed short-term and long-term event impacts, attributing values based on regulatory frameworks, economic factors, and market events.

Frequently Asked Questions

The Sweden in-vitro diagnostics market is estimated to reach USD 629.43 million by 2030.

The key players in the Sweden in-vitro diagnostics market include F. Hoffmann-La Roche AG (Roche Diagnostics), Abbott Laboratories, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Beckman Coulter AB, bioMérieux SA, Sysmex Corporation, QIAGEN N.V., DiaSorin S.p.A., Becton, Dickinson and Company, Hologic, Inc., Fujirebio Holdings, Inc., Bio-Rad Laboratories, Inc., Immunovia AB, Revvity, Inc., and Others.

The Sweden in-vitro diagnostics market was estimate to reach USD 910.96 million in 2023.

High costs associated with research, development, and regulatory approval are significant factors restraining the market growth.

Introduction of Point-of-Care Testing Solutions creates opportunities for the in-vitro diagnostics in the coming future.

Download Free Sample

Full Name *

Please Enter Full Name

Business Email Id *

Please Enter Valid Email ID

Phone Number *

Please enter Country Code and Phone No

Message

Please enter message

Yes, I have read the Privacy Policy

Purchase Options Flash
sale

Multi User

$3,217 $4595

Single User

$2,517 $3595

Enterprise

$4,617 $6595

Datapack

$1,467 $2095

Download Sample

Inquire Before Buying

Speak to Our Analyst

Share with Peers

Request Sample